Literature DB >> 8648683

Mutational analysis of human papillomavirus type 11 E5a oncoprotein.

S L Chen1, T Z Tsai, C P Han, Y P Tsao.   

Abstract

In this study, we investigated the structural basis of human papillomavirus type 11 (HPV-11) E5a transforming activity at the amino acid level. The effects of insertion, deletion , and substitution mutations on teh E5a transforming activity were determined by the assay of anchorage-independent growth. In the conserved Cys-X-Cys structure, substitution of Ser for Cys-73 resulted in indistinguishable transforming activity, whereas substitution of Ser for Cys-75 or Ser for both Cys-73 and Cys-75 retained 50 and 42% transformation, respectively. This suggests that Cys at position 75 may be important for transformation. Charge and structural changes at teh COOH termini of several mutants impaired transformation significantly, but those at the middle region did so only mildly. In addition, the 16,000-molecular-weight pore-forming protein (16K protein) is known to associate with BPV-1, HPV-6, and HPV-16 E5 proteins. In this study, we investigated the correlation between E5a-16K binding affinity and the transforming activity of E5a by the use of 11 E5a mutants. Results show that E5a and these 11 E5a mutants could bind to the 16K protein when these proteins were coexpressed in COS cells, suggesting that simple binding of the 16K protein by E5a may not be sufficient for cell transformation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648683      PMCID: PMC190224     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  A glutamine residue in the membrane-associating domain of the bovine papillomavirus type 1 E5 oncoprotein mediates its binding to a transmembrane component of the vacuolar H(+)-ATPase.

Authors:  D J Goldstein; R Kulke; D Dimaio; R Schlegel
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

2.  Bovine papillomavirus E5 oncoprotein binds to the 16K component of vacuolar H(+)-ATPases.

Authors:  D J Goldstein; M E Finbow; T Andresson; P McLean; K Smith; V Bubb; R Schlegel
Journal:  Nature       Date:  1991-07-25       Impact factor: 49.962

3.  Transforming activity of E5a protein of human papillomavirus type 6 in NIH 3T3 and C127 cells.

Authors:  S L Chen; P Mounts
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

4.  Mutational analysis of bovine papillomavirus type 1 E5 peptide domains involved in induction of cellular DNA synthesis.

Authors:  J A Rawls; P M Loewenstein; M Green
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

5.  Detection by antibody probes of human papillomavirus type 6 E5 proteins in respiratory papillomata.

Authors:  S L Chen; P Mounts
Journal:  J Med Virol       Date:  1989-12       Impact factor: 2.327

6.  Genetic evidence that acute morphologic transformation, induction of cellular DNA synthesis, and focus formation are mediated by a single activity of the bovine papillomavirus E5 protein.

Authors:  J Settleman; A Fazeli; J Malicki; B H Horwitz; D DiMaio
Journal:  Mol Cell Biol       Date:  1989-12       Impact factor: 4.272

7.  Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16.

Authors:  C Leptak; S Ramon y Cajal; R Kulke; B H Horwitz; D J Riese; G P Dotto; D DiMaio
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

8.  The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus.

Authors:  P Leechanachai; L Banks; F Moreau; G Matlashewski
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867

9.  Activation of the platelet-derived growth factor receptor by the bovine papillomavirus E5 transforming protein.

Authors:  L Petti; L A Nilson; D DiMaio
Journal:  EMBO J       Date:  1991-04       Impact factor: 11.598

10.  The E5 oncoprotein of bovine papillomavirus binds to a 16 kd cellular protein.

Authors:  D J Goldstein; R Schlegel
Journal:  EMBO J       Date:  1990-01       Impact factor: 11.598

View more
  8 in total

1.  Human papillomavirus type 11 and 16 E5 represses p21(WafI/SdiI/CipI) gene expression in fibroblasts and keratinocytes.

Authors:  Y P Tsao; L Y Li; T C Tsai; S L Chen
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

2.  Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth.

Authors:  D W Liu; Y P Tsao; C H Hsieh; J T Hsieh; J T Kung; C L Chiang; S J Huang; S L Chen
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

3.  Mucosal human papillomaviruses encode four different E5 proteins whose chemistry and phylogeny correlate with malignant or benign growth.

Authors:  Ignacio G Bravo; Angel Alonso
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  E5 proteins of human papillomavirus types 11 and 16 transactivate the c-fos promoter through the NF1 binding element.

Authors:  S L Chen; Y K Lin; L Y Li; Y P Tsao; H Y Lo; W B Wang; T C Tsai
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

5.  Identification of key amino acid residues that determine the ability of high risk HPV16-E7 to dysregulate major histocompatibility complex class I expression.

Authors:  Corina Heller; Tanja Weisser; Antje Mueller-Schickert; Elke Rufer; Alexander Hoh; Ralf M Leonhardt; Michael R Knittler
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

Review 6.  The E5 proteins.

Authors:  Daniel DiMaio; Lisa M Petti
Journal:  Virology       Date:  2013-05-31       Impact factor: 3.616

Review 7.  The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation.

Authors:  James A Scarth; Molly R Patterson; Ethan L Morgan; Andrew Macdonald
Journal:  J Gen Virol       Date:  2021-01-11       Impact factor: 3.891

8.  Golgi alkalinization by the papillomavirus E5 oncoprotein.

Authors:  F Schapiro; J Sparkowski; A Adduci; F Suprynowicz; R Schlegel; S Grinstein
Journal:  J Cell Biol       Date:  2000-01-24       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.